Stay updated on Ziltivekimab vs Placebo in Heart Failure & Inflammation Clinical Trial
Sign up to get notified when there's something new on the Ziltivekimab vs Placebo in Heart Failure & Inflammation Clinical Trial page.

Latest updates to the Ziltivekimab vs Placebo in Heart Failure & Inflammation Clinical Trial page
- CheckyesterdayChange DetectedThe Record History now shows Revision: v3.3.4 as the current version, replacing Revision: v3.3.3. This is a minor metadata update to the page label and does not affect study data or overall functionality.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedAdded Contacts/Locations and Study Status in the latest update, signaling updated trial details and contact information. An earlier version from 2025-11-25 was deleted.SummaryDifference0.3%

- Check22 days agoChange DetectedFooter area updated to show Revision: v3.3.3, and HHS Vulnerability Disclosure and Revision: v3.3.2 were removed. No study data, statuses, or history content were changed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check44 days agoChange DetectedAdded: Contacts/Locations and Study Status in version 54 (2025-11-25); Deleted: data on 2025-10-20.SummaryDifference0.3%

- Check51 days agoChange DetectedThe revision history shows the addition of v3.3.2 and the removal of v3.2.0, affecting only administrative metadata. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check58 days agoChange DetectedA government funding and operating-status notice previously shown on the page has been removed. The change does not affect trial details or the historical record of the study.SummaryDifference0.4%

Stay in the know with updates to Ziltivekimab vs Placebo in Heart Failure & Inflammation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ziltivekimab vs Placebo in Heart Failure & Inflammation Clinical Trial page.